TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer

Table 2 Associations of immune check point receptor expression in TILs with neoadjuvant chemotherapy response as calculated “MD Anderson Cancer Center (MDACC) Residual Cancer Burden Index” in TNBC patients

Expression in TILs (>%1)	N = 61 (%)	pCR(+) vs (−)^a	P- value	Class 0/I vs II/III^a	P- value	Class 0/I/II vs III^a	P- value
PD-L1 (+) vs other	29/57 (50.9%)	5/9 (56%) vs 24/47 (51%)	0.999	6/11 (55%) vs 23/45 (51%)	0.999	19/31 (61%) vs 10/25 (40%)	0.188
PD1 (+) vs other	37/61 (62%)	5/9 (56%) vs 32/51 (63%)	0.721	7/13 (54%) vs 30/47 (64%)	0.739	19/34 (56%) vs 18/26 (69%)	0.432
LAG3 (+) vs other	16/61 (26%)	2/9 (22%) vs14/51 (28%)	0.999	3/13 (23%) vs 13/47 (28%)	0.999	11/34 (32%) vs 5/26 (19%)	0.378
PD1&LAG3 (+) vs other	14/61 (23%)	2/9 (22%) vs 12/51 (24%)	0.999	3/13 (23%) vs 11/47 (23%)	0.999	9/34 (26%) vs 5/26 (19%)	0.555
TIM3 (+) vs other	42/61 (69%)	2/9 (22%) vs 39/51 (77%)	0.003	6/13 (46%) vs 35/47 (75%)	0.108	25/34 (74%) vs 16/26 (62%)	0.478
PD1&TIM3 (+) vs other	31/61 (51%)	2/9 (22%) vs 28/51 (55%)	0.145	4/13 (31%) vs 26/47 (55%)	0.209	16/34 (47%) vs 14/26 (54%)	0.794
CTLA-4 (+) vs other	50/61 (82%)	9/9 (100%) vs 40/51 (78%)	0.189	12/13 (92%) vs 37/47 (79%)	0.427	30/34 (88%) vs 19/26 (73%)	0.182
CTLA-4^b(+) vs other	43/61 (70.5%)	9/9 (100%) vs 33/51 (65%)	0.047	12/13 (92%) vs 30/47 (64%)	0.084	26/34 (77%) vs 16/26 (62%)	0.334
PD1&CTLA-4 (+) vs other	33/61 (54%)	5/9 (56%) vs 27/51 (53%)	0.999	7/13 (54%) vs 25/47 (53%)	0.999	18/34 (53%) vs 14/26 (54%)	0.999

Tumor infiltrating (stromal) lymphocytes (=TILs)
^a One patient with a residual tumor in the lymphovascular area has been excluded
^bCTLA-high expression: > 15%&any moderate or strong staining if < 15%

ISSN: 1471-2407